The estrogen-related receptor alpha (ESRRA) antibody is a key tool for studying the ESRRA protein, a member of the nuclear receptor superfamily. ESRRA, also known as ERRα, functions as a transcription factor regulating genes involved in energy metabolism, mitochondrial biogenesis, and cellular stress responses. Despite its structural similarity to estrogen receptors (ERs), ESRRA does not bind natural estrogens but instead operates in a ligand-independent manner, often interacting with coactivators like PGC-1α to modulate target gene expression.
ESRRA antibodies are widely used in research to detect ESRRA expression, localization, and interactions in various tissues and disease models. These antibodies enable techniques such as Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP), aiding investigations into ESRRA's roles in cancer, metabolic disorders, and neurodegenerative diseases. For example, elevated ESRRA levels are linked to poor prognosis in breast and ovarian cancers, while its dysregulation is implicated in type 2 diabetes and obesity.
Validating ESRRA antibodies is critical due to potential cross-reactivity with other ERR family members (ERRβ/γ) or unrelated proteins. Researchers often use knockout controls or siRNA-based approaches to confirm specificity. As ESRRA emerges as a potential therapeutic target, its antibody remains essential for unraveling its complex regulatory networks and translational applications in precision medicine.